Zhong-Ren MA, Jun-Lin LIU, Kui-Zheng CAI, Yi-Zhong LIU, Guo-Zhen LIN

Immunogenicity of Recombinant Adenovirus Co-expressing the L7/L12 and BCSP31 Proteins of Brucella abortus

Brucella insan ve hayvanlarda önemli bir tehdit olup, aşılama bakteriyi kontrol altında tutmak amacıyla iyi bir yöntem olabilir. Bu çalışmada, Brucella abortus (B. abortus) L7/L12 ve BCSP31 proteinlerini içeren rekombinant adenovirus Ad-LL/BP'nin immun yanıtı ve koruyuculuğu BALB/c farelerde araştırıldı. Adenovirus vektör Ad-CMV ve rekombinant adenovirus Ad-LL/BP, HEK 293AD hücrelerinde amplifiye edildi. Ad-LL/BP and Ad-CMV'nın TCID50 değerleri sırasıyla 10-8.68/0.1 mL ve 10-8.35/0.1 mL olarak tespit edildi. Fareler Ad-LL/BP veya Ad-CMV'nin 100 TCID50/fare ile inoküle edildi. Ad-LL/BP aşısı ile farelerin aşılanması, Ad-CMV ve PBS kontrol hayvanları ile karşılaştırıldığında daha yüksek IgG, IgG1 ve IgG2a antikor seviyelerinin olmasına neden oldu (P

Brucella abortus L7/L12 ve BCSP31 Proteinlerini Birlikte Eksprese Eden Rekombinant Adenovirusların İmmunojenitesi

Brucella poses a great threat to animal and human health, and vaccination is a good way of controlling the bacterium. In this study, the immune response and protection ability of a recombinant adenovirus Ad-LL/BP containing L7/L12 and BCSP31 proteins of Brucella abortus (B. abortus) were evaluated in BALB/c mice model. Firstly, Adenovirus vector Ad-CMV and the recombinant adenovirus Ad-LL/BP were amplified in HEK 293AD cells. The TCID50 values of Ad-LL/BP and Ad-CMV were 10−8.68/0.1 mL and 10−8.35/0.1 mL, respectively. Mice were inoculated with 100 TCID50/mouse of Ad-LL/BP or Ad-CMV. Vaccination of mice with Ad-LL/BP vaccine was able to elicit higher IgG, IgG1 and IgG2a antibody levels when compared with Ad-CMV and PBS control animals (P

PDF

___

1. Miller R, Nakavuma JL, Ssajjakambwe P, Vudriko P, Musisi N, Kaneene JB: The prevalence of Brucellosis in cattle, goats and humans in rural Uganda: A comparative study. Transbound Emerg Dis, 63 (6): e197-e210, 2016. DOI: 10.1111/tbed.12332
2. Shome R, Kalleshamurthy T, Shankaranarayana PB, Giribattanvar P, Chandrashekar N, Mohandoss N, Shome BR, Kumar A, Barbuddhe SB, Rahman H: Prevalence and risk factors of brucellosis among veterinary health care professionals. Pathog Glob Health, 111 (5): 234-239, 2017. DOI: 10.1080/20477724.2017.1345366
3. Lopes LB, Nicolino R, Haddad JPA: Brucellosis - risk factors and prevalence: A review. Open Vet Sci J, 4, 72-84, 2010. DOI: 10.2174/ 1874318801004010072
4. Rahman AKMA, Saegerman C, Berkvens D, Melzer F, Neubauer H, Fretin D, Abatih E, Dhand N, Ward MP: Brucella abortus is prevalent in both humans and animals in Bangladesh. Zoonoses Public Health, 64 (5): 394-399, 2017. DOI: 10.1111/zph.12344
5. Goodwin ZI, Pascual DW: Brucellosis vaccines for livestock. Vet Immunol Immunopathol, 181, 51-58, 2016. DOI: 10.1016/j.vetimm. 2016.03.011
6. Chand P, Chhabra R, Nagra J: Vaccination of adult animals with a reduced dose of Brucella abortus S19 vaccine to control brucellosis on dairy farms in endemic areas of India. Trop Anim Health Prod, 47 (1): 29- 35, 2015. DOI: 10.1007/s11250-014-0678-2
7. Kianmehr Z, Kaboudanian Ardestani S, Soleimanjahi H, Fotouhi F, Alamian S, Ahmadian S: Comparison of biological and immunological characterization of lipopolysaccharides from Brucella abortus RB51 and S19. Jundishapur J Microbiol, 8 (11): e24853, 2015. DOI: 10.5812/jjm.24853
8. Wang Y, Ke Y, Wang Z, Yuan X, Qiu Y, Zhen Q, Xu J, Li T, Wang D, Huang L, Chen Z: Genome sequences of three live attenuated vaccine strains of Brucella species and implications for pathogenesis and differential diagnosis. J Bacteriol, 194 (21): 6012-6013, 2012. DOI: 10.1128/ JB.01483-12
9. Yang Y, Wang L, Yin J, Wang X, Cheng S, Lang X, Wang X, Qu H, Sun C, Wang J, Zhang R: Immunoproteomic analysis of Brucella melitensis and identification of a new immunogenic candidate protein for the development of brucellosis subunit vaccine. Mol Immunol, 49 (1-2): 175- 184, 2011. DOI: 10.1016/j.molimm.2011.08.009
10. Zhang L, Wu XA, Zhang FL, An CH, Sun YX, Bai WT, Xu ZK: Soluble expression and purification of Brucella cell surface protein (BCSP31) of Brucella melitensis and preparation of anti-BCSP31 monoclonal antibodies. Mol Biol Rep, 39 (1): 431-438, 2012. DOI: 10.1007/s11033-011-0755-9
11. Du ZQ, Li X, Wang JY: Immunogenicity analysis of a novel subunit vaccine candidate molecule-recombinant L7/L12 ribosomal protein of Brucella suis. Appl Biochem Biotechnol, 179 (8): 1445-1455, 2016. DOI: 10.1007/s12010-016-2076-x
12. Du ZQ, Wang JY: A novel lumazine synthase molecule from Brucella significantly promotes the immune-stimulation effects of antigenic protein. Genet Mol Res, 14 (4): 13084-13095, 2015. D0I: 10.4238/2015. October.26.4
13. Sung KY, Jung M, Shin MK, Park HE, Lee JJ, Kim S, Yoo HS: Induction of immune responses by two recombinant proteins of Brucella abortus, outer membrane proteins 2b porin and Cu/Zn superoxide dismutase, in mouse model. J Microbiol Biotechnol, 24 (6): 854-861, 2014. DOI: 10.4014/jmb.1312.12063
14. Yu DH, Hu XD, Cai H: A combined DNA vaccine encoding BCSP31, SOD, and L7/L12 confers high protection against Brucella abortus 2308 by inducing specific CTL responses. DNA Cell Biol, 26, 435-443, 2007. DOI: 10.1089/dna.2006.0552
15. Zhou JZ, Qiu CQ, Cao XA, Lin GZ: Construction and immunogenicity of recombinant adenovirus expressing the major outer membrane protein (MOMP) of Chlamydophila psittaci in chick. Vaccine, 25, 6367- 6372, 2007. DOI: 10.1016/j.vaccine.2007.06.031
16. Arévalo MT, Xu Q, Paton JC, Hollingshead SK, Pichichero ME, Briles DE, Girgis N, Zeng M: Mucosal vaccination with a multicomponent adenovirus-vectored vaccine protects against Streptococcus pneumoniae infection in the lung. FEMS Immunol. Med Microbiol, 55, 346-351, 2009. DOI: 10.1111/j.1574-695X.2008.00518.x
17. Li D, Du Q, Wu B, Li J, Chang L, Zhao X, Huang Y, Tong D: Immunogenicity of adenovirus vaccines expressing the PCV2 capsid protein in pigs. Vaccine, 35 (36): 4722-4729, 2017. DOI: 10.1016/j.vaccine. 2017.07.031
18. Gabitzsch ES, Xu Y, Jr Balint JP, Balcaitis S, Sanders-Beer B, Jones FR: Induction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine. Vaccine, 29, 8101-8107, 2011. DOI: 10.1016/j.vaccine.2011.08.038
19. Golshani M, Rafati S, Gholami E, Siadat SD, Oloomi M, Bouzari S: Vaccination with recombinant L7/L12-Truncated Omp31 protein induces protection against Brucella infection in BALB/c mice. Mol Immunol, 65, 287-292, 2015. DOI: 10.1016/j.molimm.2015.01.009
20. Miravet S, Ontiveros M, Piedra J, Penalva C, Monfar M, Chillon M: Construction, production, and purification of recombinant adenovirus vectors. Methods Mol Biol, 1089, 159-173, 2014. DOI: 10.1007/978-1- 62703-679-5_12
21. Golshani M, Rafati S, Nejati-Moheimani M, Ghasemian M, Bouzari S: Comparison of potential protection conferred by three immunization strategies (protein/protein, DNA/DNA, and DNA/protein) against Brucella infection using Omp2b in BALB/c Mice. Vet Microbiol, 197, 47-52, 2016. DOI: 10.1016/j.vetmic.2016.10.027
22. Oliveira SC, Macedo GC, De Almeida LA, De Oliveira FS, Oñate A, Cassataro J, Giambartolomei GH: Recent advances in understanding immunity against brucellosis: Application for vaccine development. Open Vet Sci J, 4, 102-108. 2010. DOI: 10.2174/1874318801004010102
23. Khanam S, Pilankatta R, Khanna N, Swaminathan S: An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Vaccine, 27, 6011-6021, 2009. DOI: 10.1016/j.vaccine.2009.07.073
24. Singh D, Goel D, Bhathagar R: Recombinant L7/L12 protein entrappiing PLGA (poly-co-glycolide) micro particles protect BALB/c mice against the virulent B. abortus 544 infection. Vaccine, 33, 2786-2792, 2015. DOI: 10.1016/j.vaccine.2009.07.073
25. Li JY, Liu Y, Gao XX, Gao X, Cai H: TLR2 and TLR4 signaling pathways are required for recombinant Brucella abortus BCSP31-induced cytokine production, functional upregulation of mouse macrophages, and the Th1 immune response in vivo and in vitro. Cell Mol Immunol, 11, 477-494, 2014. DOI: 10.1038/cmi.2014.28
26. Golshani M, Rafati S, Gholami E, Siadat SD, Oloomi M, Bouzari S: Vaccination with recombinant L7/L12-Truncated Omp31 protein induces protection against Brucella infectionin BALB/c mice. Mol Immunol, 65, 287-292, 2015. DOI: 10.1016/j.molimm.2015.01.009
27. Golshani M, Rafati S, Siadat SD, Nejati-Moheimani M, Shahcheraghi F, Arsang A, Bouzari S: Improved immunogenicity and protective efficacy of a divalent DNA vaccine encoding Brucella L7/L12-truncated Omp31 fusion protein by a DNA priming and protein boosting regimen. Mol Immunol, 66, 384-391, 2015. DOI: 10.1016/j.molimm.2015.04.015